Impact of Formulary Coverage of Entresto (Sacubitril/Valsartan) on Prescription Abandonment/Rejection and Subsequent Treatment and Economic Outcomes in Chronic Heart Failure Patients in the U.S. - Trial NCT05848206
Access comprehensive clinical trial information for NCT05848206 through Pure Global AI's free database. This phase not specified trial is sponsored by Novartis Pharmaceuticals and is currently Completed. The study focuses on Chronic Heart Failure. Target enrollment is 251831 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Observational
Sponsor & Location
Novartis Pharmaceuticals
Novartis
Timeline & Enrollment
N/A
Mar 11, 2022
Apr 29, 2022
Primary Outcome
Percentage of patients who had SAC/VAL prescriptions filled,Percentage of patients who had abandoned (not accepted) SAC/VAL prescriptions,Percentage of patients who had SAC/VAL prescriptions rejected by an insurance payer
Summary
This was a retrospective cohort study utilizing IQVIA open-source pharmacy and medical claims
 data among patients with a sacubitril/valsartan (SAC/VAL) prescription transaction.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05848206
Non-Device Trial